Affordable Access

Effect of nebulized furosemide in terminally ill cancer patients with dyspnea.

Authors
Type
Published Article
Journal
Journal of Pain and Symptom Management
0885-3924
Publisher
Elsevier
Publication Date
Volume
26
Issue
4
Pages
962–967
Identifiers
PMID: 14575057
Source
Medline
License
Unknown

Abstract

We evaluated the effect of ultrasonically nebulized furosemide (20 mg) on dyspnea uncontrollable by standard therapy in patients with terminal cancer. Dyspnea was evaluated using the Cancer Dyspnea Scale (CDS) before and 60 min after inhalation. Changes in arterial blood gases, hemoglobin oxygen saturation (SpO2), heart rate (HR), and respiratory rate (RR) also were evaluated. In 12 of 15 patients (80%), total dyspnea scores by CDS improved significantly after inhalation of furosemide (P = 0.007), especially concerning a reduced sense of effort (P = 0.013) and reduced anxiety (P = 0.04). No significant changes were observed in the partial pressure of oxygen in arterial blood (PaO2), the partial pressure of carbon dioxide in arterial blood (PaCO2), SpO2, HR, or RR. Inhalation of nebulized furosemide appears to be effective against dyspnea in terminally ill cancer patients.

Statistics

Seen <100 times